Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioExx Specialty Proteins Ltd BIXZF

"Bioexx Specialty Proteins Inc is engaged in the development and commercialization of processing technologies, for use in the extracting various active ingredients from organic and inorganic materials. The company's primary focus is on the production of proteins from canola and other oilseed feedstocks. Its products include Isolexx, a protein isolate for use in bakery products, meat products, vegetarian food products and meat analogues, and nutritional and protein bars, drinks, and supplements;


GREY:BIXZF - Post by User

Post by conscience1on Apr 02, 2013 10:47pm
252 Views
Post# 21202422

So it IS possible...

So it IS possible...

...to add a protein-production facility to an oil-pressing plant. The prospective partner (maybe not Helm AG) must have a low-temp method for oil pressing. Maybe it's becoming more common. Good news for us.

Wouldn't it be interesting if other potential  food conglomerates had second thoughts on BXI before a binding contract can be drafted? I hope TMX will be sure to send this week's news to potentially interested parties.

Hopefully the terms of a deal include an endpoint, similar to those for small companies who develop new drugs, when the original patent and its use revert to the original company. For example, after the partners have been compensated for their risk and financial backing. Something tells me CS doesn't need my amateur help. His logical approach and careful steps may well lead to a big payoff for us longs.

Believe! GLTA

 

 

<< Previous
Bullboard Posts
Next >>